A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
出版年份 2021 全文链接
标题
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
作者
关键词
chronic kidney disease, dapagliflozin, DAPA-CKD, IgA nephropathy, randomized controlled clinical trial, sodium-glucose cotransporter inhibitor
出版物
KIDNEY INTERNATIONAL
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-04-19
DOI
10.1016/j.kint.2021.03.033
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
- (2021) Taha Sen et al. Cell Metabolism
- What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
- (2020) Vikas S. Sridhar et al. DIABETES OBESITY & METABOLISM
- After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.
- (2020) Thomas Rauen et al. KIDNEY INTERNATIONAL
- Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
- (2020) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
- (2020) David C Wheeler et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Why Target the Gut to Treat IgA Nephropathy?
- (2020) Jonathan Barratt et al. Kidney International Reports
- Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
- (2020) David C Wheeler et al. Lancet Diabetes & Endocrinology
- Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease
- (2020) John J.V. McMurray et al. CIRCULATION
- Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- (2019) Jürgen Floege et al. KIDNEY INTERNATIONAL
- New strategies and perspectives on managing IgA nephropathy
- (2019) Haresh Selvaskandan et al. Clinical and Experimental Nephrology
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
- (2019) Hiddo J L Heerspink et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy
- (2017) Jicheng Lv et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
- (2017) Bengt C Fellström et al. LANCET
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
- (2015) Volker Vallon Annual Review of Medicine
- Intensive Supportive Care plus Immunosuppression in IgA Nephropathy
- (2015) Thomas Rauen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- IgA Nephropathy
- (2013) Robert J. Wyatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Corticosteroid Therapy in IgA Nephropathy
- (2012) J. Lv et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Omega3 Fatty Acids Ameliorate Proteinuria but Not Renal Function in IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials
- (2012) Hsin-Hsu Chou et al. NEPHRON CLINICAL PRACTICE
- ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials
- (2009) J. Cheng et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: A long-term follow up of 204 cases in China
- (2008) JICHENG LV et al. NEPHROLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started